GPT and type 2 diabetes mellitus: The use of this molecule in a phase 2 randomized trial of patients with T2DM demonstrated a significant reduction in NASH-related biomarkers (AST/ALT, keratin 18, fragment M30, procollagen III) and an increase in adiponectin levels, which has antifibrotic and antisteatogenic activity in the liver [73].